Chronic Kidney Disease

A novel program utilizing an approach to defragment care for patients with end-stage kidney disease (ESKD) resulted in better patient outcomes.

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.

The data show the average age of dialysis in the least vulnerable neighborhoods was 68.2 years old, but 59.4 years—almost a decade earlier—in the most vulnerable.

Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).

The authors developed an algorithm that uses medical claims to identify patients with chronic kidney disease who are at greatest risk of being hospitalized within 90 days.

CEOs of 3 kidney care organizations explain flaws in CMS' recent reimbursement proposal.

Medicare prospective payment for dialysis modestly increased availability and use of home-based dialysis treatment but did not affect historic racial disparities in home dialysis.

Unrecognized disease progression is associated with higher health care costs both for patients with end-stage kidney disease and late-stage (stages G4-G5) chronic kidney disease.

A planned transition to dialysis was associated with improved outcomes and lower mortality. These findings may inform care coordination policies for end-stage renal disease.

Data released in the CDC’s latest Morbidity and Mortality Weekly Report indicate that patients with end-stage kidney disease on hemodialysis who are Black, Hispanic/Latino, or of lower socioeconomic status (SES) are at greater risk of Staphylococcus aureus bloodstream infections, with Hispanic/Latino ethnicity cited as an independent risk factor.

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States.

The top 5 most-read articles about chronic kidney disease (CKD) focused on finerenone benefits, anticoagulants, dementia association, and more.

Kidney Week 2022 focused on effectiveness of treatment for chronic kidney disease, health misinformation, and outcomes in chronic kidney disease, among other topics.

Lower estimated tubular secretion was found to be associated with a faster decline of estimated glomerular filtration rate (eGFR) but wasn’t associated with progression of chronic kidney disease or cardiovascular disease.

A retrospective study found roxadustat to be more effective in improving hemoglobin levels in patients who had with chronic kidney disease (CKD) compared with recombinant human erythropoietin.

Implantable cardioverter defibrillators (ICDs) were found to have a beneficial effect on mortality in patients with chronic kidney disease (CKD).

Prescriptions for treatment of atrial fibrillation (AF) and chronic kidney disease (CKD) have primarily been prescriptions for direct oral anticoagulants (DOACs), displacing warfarin as the primary treatment.

A cohort study found that chronic kidney disease (CKD) was associated with the development of abdominal aortic aneurysm, with risk increasing as CKD stage advanced.

Speaking with patients diagnosed with chronic kidney disease (CKD) about the burdens associated with care could help improve understanding of the disease and their communication with health care professionals.

Treatment with an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker and sodium-glucose cotransporter-2 (SGLT2) inhibitor combination demonstrated better outcomes in kidney failure.

A new review has found that increased incidence of chronic kidney disease (CKD) may be seen among patients with nonalcoholic fatty liver disease.

Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.

The studies reviewed estimates of economic and humanistic impact on both patients with chronic kidney disease (CKD) as well as their caregivers.

Updated Kidney Disease: Improving Global Outcomes guidelines and a consensus report with the American Diabetes Association support the use of finerenone in certain patients who have chronic kidney disease (CKD) that may be linked to type 2 diabetes (T2D).

FDA advisers voted in favor of approving Ardelyx’s tenapanor for patients with chronic kidney disease on dialysis; US home births increased by about 12% between 2020 and 2021; surges in respiratory viruses, especially respiratory syncytial virus (RSV) among younger children are putting pediatric hospitals at capacity.

A prospective population-based cohort study found that glomerular filtration rate based on cystatin C was more sensitive and specific for cardiovascular disease (CVD) and mortality risks compared with glomerular filtration rate based on creatinine.

A systematic review found that alternative approaches to calculating estimated glomerular filtration rate (eGFR) were worth looking into to properly account for diversity in populations.

The author, the dean of the College of Ethnic Studies at California State University Los Angeles, says a Supreme Court ruling could upend insurance protections for patients with kidney diseases, disproportionately hurting those who are Black, Hispanic, Asian, and other diverse ethnicities.

The launch of the National Kidney Foundation’s first nationwide registry of patients with kidney disease could help link patient data with laboratory and clinical information.

A cross-sectional study found that severe anemia was common in patients with chronic kidney disease (CKD) and was associated with lower glomerular filtration rate (eGFR) and multiple adverse outcomes.